undamentalytics Newsletter
Sign in

Xtant Medical Holdings, Inc. income statement

In fiscal 2025, Xtant Medical Holdings, Inc. reported revenue of $134m, up 14.2% on the year before, operating income of $7.3m (a 5.4% margin) and net income of $5.0m, or $0.03 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1530333335599083726553555891117134110
Cost of revenue—9101413202833292219232636495044
Gross profit1221231922396250434334323255688465
Research and development———11332211111222
Selling and marketing919161617294441312621212338494641
General and administrative9711109131615141714141526292927
Operating income−9−6−5−9−6−12−8−38−60−2−1−4−7−10−127−10
Interest expense21256812151066123443
Income before tax−19−3−8−13−11−20−19−52−70−8−7−5−8−1−167−9
Income tax——000−1800—00—0−2022
Net income−19−3−8−13−11−2−19−52−70−8−7−5−81−165−11
Diluted EPS−$3.05−$0.00−$0.01−$1.40−$0.07−$0.01−$0.77−$1.45−$1.99−$0.21−$0.08−$0.06−$0.09$0.01−$0.12$0.03−$0.08
Diluted shares (average)6m8m8m9m12m18m25m36m35m39m85m85m94m127m134m150m147m
EBITDA−8−6−4−8−5−7−0−29−5311−3−5−7−813−7

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: SMTI vs XTNTOWLT vs XTNTCBLL vs XTNT

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Xtant Medical Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Xtant Medical Holdings, Inc.